Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.
Elvitegravir (EVG), an integrase inhibitor for the treatment HIV infection, is increasingly becoming the part of first-line antiretroviral therapy (ART) regimen. EVG is mainly metabolized through cytochrome P450 (CYP) 3A4. Previously, we have shown that ethanol alters ART-CYP3A4 interactions with pr...
Main Authors: | Narasimha M Midde, Mohammad A Rahman, Chetan Rathi, Junhao Li, Bernd Meibohm, Weihua Li, Santosh Kumar |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4752462?pdf=render |
Similar Items
-
Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.
by: Narasimha M Midde, et al.
Published: (2017-01-01) -
Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS
by: Prinapori R, et al.
Published: (2015-08-01) -
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
by: Neamati Nouri, et al.
Published: (2009-03-01) -
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors
by: Neamati Nouri, et al.
Published: (2009-04-01) -
Novel elvitegravir nanoformulation approach to suppress the viral load in HIV-infected macrophages
by: Yuqing Gong, et al.
Published: (2017-12-01)